WAKE-UP trial has a positive result!

WAKE-UP trial has a positive result!

WAKE-UP has provided a new treatment option for stroke patients if it is not known when their stroke started.

Up to 20 per cent of stroke patients wake up in the morning with stroke symptoms. This means that the time when their stroke started is unknown and so they are not routinely eligible for clot-busting treatment (thrombolysis) with drugs such as as alteplase, which is only approved to be used within 4.5 hours after the start of stroke symptoms. Every year about two million patients have a stroke in the EU, including approximately 400.000 patients with ‘wake-up- stroke’ or who otherwise have unknown time of symptom onset.

Now, the WAKE-UP study has revealed for the first time that selecting patients for treatment based on what is shown in their MRI brain images can be used to decide if they get thrombolysis. By comparing different images from the MRI examination, clinicians can now deduce when a stroke is likely to have started, and whether a patient is likely to benefit from thrombolysis. (more…)

WAKE-UP trial has a positive result!

What does the Stroke Support Faculty Tool (SSOFT) mean to me?

Posted on Friday May 11, 2018 by The Foundry Healthcare

I am a child of immigration. Both my parents came to the UK for their education, and because of this the value and importance of education has been a strong influence in my life. I believe that education can equalise the playing field, it can transform the potential of anyone and can create real change. To me the Stroke Support Organisation Faculty Tool, SSOFT, incorporates these important aspects; equal access, increased potential and the means to change things for the better. (more…)

Stroke Medical Experts and Stroke Advocates Present a Joint Plan to Combat Stroke

Stroke Medical Experts and Stroke Advocates Present a Joint Plan to Combat Stroke

Stroke Action Plan for Europe 2018-2030

Basel and Brussels, 11 May 2018 – Just one year after signing a Memorandum of Understanding, the European Stroke Organisation (ESO) and the Stroke Alliance for Europe (SAFE) are proud to present the “The Stroke Action Plan for Europe 2018-2030”, with the aim of significantly improving stroke care and Life after Stroke for the millions of people expected to have strokes over the next 12 years.

ESO and SAFE will present the Stroke Action Plan for Europe to the medical world for the first time in a joint session at ESOC in Gothenburg on Thursday, 17 May. In addition to speakers from ESO and SAFE, the World Health Organisation (WHO) perspective on Joining Forces in Combating Stroke in Europe will be presented. (more…)

Today is European Stroke Awareness Day 2018!

Today is European Stroke Awareness Day 2018!

The Stroke Alliance for Europe (SAFE) and its members from 30 European countries are committed to raising awareness of stroke

Brussels, 8th May 2018- This May, SAFE and its members have many activities to be proud of. We have managed to successfully complete a joint project with the European Stroke Organisation (ESO), the Stroke Action Plan for Europe 2018-2030.

The project will first be presented to the medical world at this year’s European Stroke Congress in Gothenburg, Sweden on Thursday, 17 May 2018.

After that, the main recommendations in the Stroke Action Plan will be launched to politicians and the public at the European Parliament on 23 May at the 2nd EU Stroke Summit. (more…)

SONIA: An imaging software that could significantly influence lives of people who woke up with a stroke

SONIA: An imaging software that could significantly influence lives of people who woke up with a stroke

SONIA

Jan Klein; Photo by Fraunhofer MEVIS

Stroke is a devastating disease leading to death and disability in large numbers of patients with massive social and economic impact. Intravenous thrombolysis with Alteplase is available as an effective and safe treatment of acute stroke if given within 4.5 hours of symptom onset.

However, in about 20% of acute stroke patients the time of symptom onset is unknown e.g. because symptoms are recognized when waking-up from sleep in the morning. This large group of patients is currently excluded from treatment with Alteplase only due to the missing information on the time of symptom onset.

WAKE-UP was a European multicentre investigator-initiated randomized placebo-controlled clinical trial of MRI based thrombolysis in acute stroke patients with unknown time of symptom onset.

In preparatory work, the WAKE-UP consortium developed an innovative approach of using brain MRI as surrogate marker of stroke lesion age which may be used to identify stroke patients likely to benefit from thrombolysis.

The final results of this trial will be presented at the press conference within ESOC 2018, in Gothenburg, Sweden, from 11:40 to 11:50 CET on Wednesday, 16 May.

As the revealing of the WAKE UP trial results approaches, SAFE used the opportunity to talk with the two scientists, Jan Klein from the Fraunhofer Institute for Medical Image Computing MEVIS, Bremen, Germany and Bastian Cheng, from School of Medicine and University Hospital Hamburg-Eppendorf to learn more about SONIA – the diagnostic imaging software that was developed during the course of the project. (more…)